Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Inclusion Criteria: * Kidney biopsy confirmed Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) * For Minimal Change Disease patients only, history of resistance to corticosteroid therapy * Increased urinary excretion of biomarkers of Tumor Necrosis Factor (TNF) activation (MCP1/Cr and/ or TIMP1/Cr) at study screening * eGFR\>30 ml/min/1.73 m2 at screening * Urine protein:creatinine ratio ≥1.5 g/g at screening * Weight \>15 kg * Stable therapy with angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and oral immunosuppression agents for at least 30 days prior to enrollment * Birth control use in females of child bearing potential * Informed consent and assent if applicable Exclusion Criteria: * Kidney or other solid organ or bone marrow transplant recipient * Allergy or intolerance to investigational agent * Secondary Focal Segmental Glomerulosclerosis (FSGS) * Severe obesity * Live virus vaccine in the past 3 months * Malignancy, current or in the past 5 years * Active local or systemic bacterial, fungal or viral infection * Active or latent Hepatitis B, Hepatitis C, HIV, or tuberculosis * History of demyelinating disease, e.g. Multiple Sclerosis or Guillain-Barre * History of heart failure * Active liver disease * Systemic lupus erythematosus or ANA \> 1:80 * History of inflammatory bowel disease, e.g. ulcerative colitis or Crohns disease * Cyclophosphamide in past 90 days, Rituximab in the past 180 days * Pregnancy or nursing…